Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
This is an open-label, non-randomized, two arm, Phase I research study of superselective intraarterial Cetuximab (Erbitux) with or without radiation therapy for treatment of recurrent unresectable squamous cell carcinoma of the head and neck (HNSCC).
Carcinoma, Squamous Cell|Carcinoma, Squamous Cell of Head and Neck
DRUG: Intraarterial Cetxuimab (Erbitux)
The maximum tolerated dose (MTD) of superselective intraarterial Cetuximab., 30 days|Descriptive frequency of subjects experiencing toxicities., 30 days
This is an open-label, non-randomized, two arm, Phase I research study of superselective intraarterial Cetuximab (Erbitux) with or without radiation therapy for treatment of recurrent unresectable squamous cell carcinoma of the head and neck (HNSCC).